Skip to main content
Equibles
TSHA logo

TSHA · Taysha Gene Therapies, Inc. · Metrics

Track TSHA — free

Use TSHA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TSHA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.25 +0.24 (+5.99%) At close · Oct 27 Q2 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$1.36B
Shares
325.83M
Volume · Oct 27 2.82M Avg daily vol (3M) 3.55M

TSHA metrics

77 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$4.25
Market cap
$1.36B

Price action

20 metrics
Price change (1W)
+1.8%
Price change (30D)
-19.6%
Price change (3M)
-27.6%
Price change (6M)
-37.9%
Price change (YTD)
-27.1%
Price change (1Y)
-15.6%
Trailing year
Price change (5Y)
-75.2%
52-week high
$6.98
52-week low
$3.51
Change from 52-week high
-42.6%
Change from 52-week low
+14.2%
Annualized volatility
72.0%
Annualized volatility (3M)
59.0%
Beta
1.9
RSI (14D)
39.7
Price vs SMA 50
-19.5%
Price vs SMA 200
-24.9%
Avg volume (3M)
3.54M
Relative volume
0.5
Average dollar volume
$17.85M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
325.83M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
163.9×
reciprocal yield 0.6%
EV / EBITDA
—
EV / EBIT
—
P / sales
237.9×
reciprocal yield 0.4%
P / book
3.4
reciprocal yield 29.7%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-11.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
99.0×
reciprocal yield 1.0%
EV / revenue historical average (5Y)
99.0×
reciprocal yield 1.0%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-11

Profitability

9 metrics
Gross margin
—
Operating margin
-2,792.3%
Trailing 12 months
Net margin
-2,728.0%
Gross profit (TTM)
—
Operating profit (TTM)
−$153.16M
Net income (TTM)
−$149.63M
Trailing 12 months
Diluted EPS (TTM)
$-0.42
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.02
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-0.42
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-0.41
Operating cash flow per diluted share (TTM)
$-0.36
Free cash flow per diluted share (TTM)
$-0.32
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$0.34
Stock compensation per diluted share (TTM)
$0.05
Book value per share
$0.87

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$5.49M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+23.8%
Year over year · more shares
Revenue CAGR (3Y)
+57.5%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-38.6%
Return on assets
-31.8%
Debt / equity
0.1
Current ratio
17.8
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
17.8
Interest coverage
-3,646.6
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$406.15M
Latest balance sheet
Cash & equivalents
$455.41M
Total assets
$470.43M
Total debt
$49.26M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$132.19M
Capital expenditures (TTM)
$381,000
R&D (TTM)
$123.14M
SG&A (TTM)
—
Stock compensation (TTM)
$18.17M
R&D / revenue
2,245.1%
Stock compensation / revenue
331.3%

Ownership (13F)

9 metrics
13F filers
208
13F filer change QoQ
+15
Institutional ownership
92.2%
Conviction holders (share of 13F filers)
1.9%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+14.4%
Holder tenure
10.8
Price vs estimated holder cost
+102.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
12.8%

Short interest

3 metrics
Short interest
15.7%
Latest settlement · 11.6 days to cover
Days to cover
11.6d
Short-squeeze score
65 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1806310 CUSIP 877619106 13F (30d) 19 filings 19 filers Visit website Investor relations